Cutaneous Oncology News

A phase 3 study of Ameluz and RhodoLED photodynamic therapy for superficial basal cell carcinoma has reached a key milestone as the final patient has completed the 1-year follow-up visit, Biofrontera announced in a press release.

A novel topical gel, HT-001, has shown potential as a treatment for cutaneous side effects from epidermal growth factor receptor inhibitor cancer therapy, according to a Hoth Therapeutics press release detailing phase 2a interim data.

Recurrence-free survival and overall survival were more common in patients with nevus-associated acral melanoma compared with those with de novo acral melanoma, according to a study.

The risk for melanoma-related death increased among patients with T1 melanoma tumors thicker than 0.8 mm, according to a study.

Ambient ultraviolet radiation exposure and Merkel cell polyomavirus were both attributed to the development of Merkel cell carcinoma, whereas HIV, organ transplants and lymphocytic leukemia were not, according to a study.

Metformin may have potential in preventing nonmelanoma skin cancer, including in most populations with skin of color, according to a study.

As the year comes to a close, Healio Dermatology has assembled this year’s most-read cutaneous oncology articles.

Healio spoke to the president of the American Academy of Dermatology after the organization issued a letter to the editor of The Atlantic with “serious concerns” over its article entitled “Against sunscreen absolutism.”

The FDA approved cosibelimab-ipdl for the treatment of certain patients with cutaneous squamous cell carcinoma.